Orforglipron vs Tirzepatide

Overview

Orforglipron and tirzepatide represent different approaches to incretin therapy. Orforglipron is an oral, non-peptide, small molecule GLP-1 agonist taken daily, while tirzepatide is an injectable dual GIP/GLP-1 agonist given weekly. Both are from Eli Lilly, representing complementary portfolio options.

Mechanism Comparison

Aspect	Orforglipron	Tirzepatide
Targets	GLP-1 only	GIP + GLP-1
Molecule Type	Small molecule	Peptide
Route	Oral	Injectable

Key Distinctions

Orforglipron advantages:

• Oral administration (no injections)
• Small molecule (easier manufacturing, storage)
• No food timing restrictions (unlike semaglutide oral)
• Potential cost advantages

Tirzepatide advantages:

• Dual agonism (GIP adds efficacy)
• Weekly dosing (less frequent)
• Higher weight loss demonstrated
• FDA approved

Evidence Comparison

Aspect	Orforglipron	Tirzepatide
Development Phase	Phase 3	FDA Approved
Key Trials	ACHIEVE program	SURMOUNT, SURPASS
Human Data	Phase 2 published	Extensive
Regulatory Status	Investigational	Approved (Mounjaro, Zepbound)

Efficacy Comparison

Orforglipron (Phase 2)

Dose	Weight Loss (36 weeks)
36mg	~9.4%
45mg	~10.1%

Tirzepatide (SURMOUNT-1)

Dose	Weight Loss (72 weeks)
5mg	~15%
10mg	~19.5%
15mg	~22.5%

Key point: Tirzepatide shows greater weight loss, likely due to dual agonism.

Regulatory Status

Aspect	Orforglipron	Tirzepatide
FDA Status	Phase 3	Approved
Indications	Obesity, T2D (in trials)	T2D, Obesity
Brand Names	N/A	Mounjaro, Zepbound
Expected Approval	2025-2026	Already approved

Administration Comparison

Factor	Orforglipron	Tirzepatide
Route	Oral tablet	Subcutaneous injection
Food Restrictions	None	None (injectable)
Storage	Room temperature	Refrigerated
Self-administration	Simple	Requires injection technique

Patient Preference Considerations

Factor	Oral (Orforglipron)	Injectable (Tirzepatide)
Needle phobia	No barrier	Barrier for some
Daily compliance	Required	Less frequent
Travel convenience	Easier	Requires cold chain
Perceived efficacy	Lower (GLP-1 only)	Higher (dual agonist)

Side Effect Profile

Effect	Orforglipron	Tirzepatide
Nausea	Common	Common
Vomiting	Common	Common
Diarrhea	Common	Common
Discontinuation	~10-15% (Phase 2)	~5-7%

GI effects are class-related; oral route doesn’t eliminate them.

Manufacturing and Access

Factor	Orforglipron	Tirzepatide
Molecule Type	Small molecule	Peptide
Manufacturing	Chemical synthesis	Biologic production
Scalability	Potentially easier	More complex
Supply Challenges	TBD	Current shortages
Generic Potential	Standard small molecule	Biologic complexity

Small molecule manufacturing may help address supply constraints.

Cost Considerations

Factor	Orforglipron	Tirzepatide
Expected Pricing	TBD	~$1,000+/month (US)
Manufacturing Cost	Potentially lower	Higher (peptide)
Insurance Coverage	TBD	Variable

Key Differences

• Efficacy: Tirzepatide shows greater weight loss (dual agonism)
• Convenience: Orforglipron is oral (no injections)
• Frequency: Orforglipron daily vs tirzepatide weekly
• Approval status: Tirzepatide approved; orforglipron investigational
• Molecule type: Small molecule vs peptide

Portfolio Strategy

Eli Lilly’s approach:

• Tirzepatide: Maximum efficacy, injectable
• Orforglipron: Oral option, broader access
• Retatrutide: Next-gen triple agonist (pipeline)

Different patient populations may prefer different options.

Summary

• Orforglipron offers oral convenience with ~10% weight loss - suitable for patients preferring pills
• Tirzepatide provides superior efficacy (~20%+ weight loss) but requires weekly injections
• Dual agonism appears to confer efficacy advantage over GLP-1 alone
• Market may segment by patient preference and indication severity
• Both likely to have roles in obesity treatment

---

This comparison is for educational purposes only. Orforglipron is investigational. Consult a healthcare provider for treatment decisions.